Additionally, BECN1 contributes to the progression of established tumors by inactivating BECN1 through the overexpression of phosphomimetic mutants in non-small cell lung carcinoma (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations [33], and also HER2+ breast cancers treated with a BECN1-dependent autophagy inducer also inhibit tumor growth [34]. Here, ERBB2 is linked to breast carcinoma.